Showing results (511-520 of 665) with videos related to

Sort By:
Pageof 67
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2001
The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratificationR J Hicks, V Kalff, M P MacManus, et al.
British Journal of Haematology|April 1, 1996
Association of acquired Pelger-Huet anomaly with taxoid therapyS K Juneja, J P Matthews, R Luzinat, et al.
Clinical Pharmacology and Therapeutics|June 13, 2023
Considerations for Cell and Gene Therapy Programs Entering the Clinical SpaceGeoffrey A Walford, An Bautmans, Carol Cannon, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile InfectionKa Lai Yee, Huub Jan Kleijn, Thomas Kerbusch, et al.
Antimicrobial Agents and Chemotherapy|March 5, 2025
Pharmacokinetics of islatravir in participants with moderate hepatic impairmentRandolph P Matthews, Munjal Patel, Wen Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A randomised double blind crossover study of domperidone and prochlorperazine suppositories for controlling emesis in outpatients receiving chemotherapyI N Olver, C R Laidlaw, J P Matthews, et al.
Physical Chemistry Chemical Physics : PCCP|March 19, 2015
An OHD-RIKES and simulation study comparing a benzylmethylimidazolium ionic liquid with an equimolar mixture of dimethylimidazolium and benzeneLianjie Xue, George Tamas, Richard P Matthews, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancerMichael P Mac Manus, Rodney J Hicks, Jane P Matthews, et al.
Leukemia & Lymphoma|July 31, 1998
Prognostic markers of disease activity in Hodgkin's diseaseA J Martinow, K Yuen, I A Cooper, et al.
Pageof 67